Total Payments
$65,933
2024 Payments
$1,586
Companies
38
Transactions
282
Medicare Patients
7,454
Medicare Billing
$402,794
Payment Breakdown by Category
Research$58,205 (88.3%)
Food & Beverage$7,539 (11.4%)
Education$188.88 (0.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $58,205 | 5 | 88.3% |
| Food and Beverage | $7,539 | 271 | 11.4% |
| Education | $188.88 | 6 | 0.3% |
Payments by Type
Research
$58,205
5 transactions
General
$7,728
277 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $58,205 | 5 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $1,094 | 32 | $0 (2024) |
| Amgen Inc. | $829.60 | 32 | $0 (2023) |
| Novo Nordisk Inc | $714.69 | 32 | $0 (2023) |
| Lumenis BE inc | $595.03 | 1 | $0 (2024) |
| Allergan, Inc. | $588.39 | 33 | $0 (2022) |
| REVANCE THERAPEUTICS, INC. | $560.53 | 8 | $0 (2024) |
| ABBVIE INC. | $431.85 | 12 | $0 (2024) |
| PFIZER INC. | $380.80 | 12 | $0 (2023) |
| Lilly USA, LLC | $296.61 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,586 | 16 | Lumenis BE inc ($595.03) |
| 2023 | $732.44 | 20 | Amgen Inc. ($127.80) |
| 2022 | $3,081 | 36 | Eli Lilly and Company ($2,260) |
| 2021 | $42,193 | 32 | Eli Lilly and Company ($41,430) |
| 2020 | $14,961 | 29 | Eli Lilly and Company ($14,515) |
| 2019 | $1,001 | 36 | AstraZeneca Pharmaceuticals LP ($342.37) |
| 2018 | $1,063 | 47 | AstraZeneca Pharmaceuticals LP ($376.21) |
| 2017 | $1,316 | 66 | PFIZER INC. ($354.21) |
All Payment Transactions
282 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $124.40 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 12/06/2024 | Lumenis BE inc | M22 (Device) | Food and Beverage | Cash or cash equivalent | $595.03 | General |
| Category: Dermathology | ||||||
| 10/01/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $17.03 | General |
| 09/30/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Respiratory | ||||||
| 08/23/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: FACIAL AESTHETICS | ||||||
| 08/23/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: FACIAL AESTHETICS | ||||||
| 07/25/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $52.00 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 07/25/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $33.38 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 07/10/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $115.54 | General |
| 06/08/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $126.15 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 04/24/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: FACIAL AESTHETICS | ||||||
| 03/28/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $27.93 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 03/27/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $29.86 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 02/20/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $32.58 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 02/07/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $134.23 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 01/02/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $104.04 | General |
| 09/28/2023 | Amgen Inc. | Prolia (Biological) | Food and Beverage | In-kind items and services | $97.43 | General |
| Category: Bone Health | ||||||
| 09/26/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: Inflammation | ||||||
| 09/20/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $20.20 | General |
| Category: Diabetes | ||||||
| 09/01/2023 | Medtronic, Inc. | INTERSTIM (Device) | Food and Beverage | In-kind items and services | $118.48 | General |
| Category: Sacral Nerve Stimulation | ||||||
| 08/17/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $110.42 | General |
| Category: Diabetes | ||||||
| 08/15/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $9.49 | General |
| Category: Inflammation | ||||||
| 07/03/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA, SHINGRIX | Food and Beverage | In-kind items and services | $25.59 | General |
| Category: RESPIRATORY | ||||||
| 06/14/2023 | Ironwood Pharmaceuticals, Inc | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $17.61 | General |
| Category: GI | ||||||
| 05/21/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: RESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $51,530 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $4,415 | 1 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $2,260 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 367 | 1,109 | $73,429 | $27,679 |
| 2022 | 33 | 1,387 | 2,780 | $156,813 | $79,971 |
| 2021 | 38 | 2,123 | 4,324 | $204,919 | $92,473 |
| 2020 | 60 | 3,577 | 12,002 | $422,992 | $202,671 |
Total Patients
7,454
Total Services
20,215
Medicare Billing
$402,794
Procedure Codes
148
All Medicare Procedures & Services
148 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 44 | 301 | $27,888 | $10,639 | 38.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 22 | 149 | $14,326 | $5,348 | 37.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 37 | 70 | $10,108 | $3,444 | 34.1% |
| 97110 | Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | Office | 2023 | 18 | 133 | $6,230 | $2,194 | 35.2% |
| 97112 | Therapy procedure to re-educate brain-to-nerve-to-muscle function, each 15 minutes | Office | 2023 | 24 | 76 | $3,816 | $1,768 | 46.3% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 20 | 60 | $4,620 | $1,751 | 37.9% |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | Office | 2023 | 24 | 113 | $2,147 | $763.38 | 35.6% |
| 97032 | Application of electrical stimulation with therapist present, each 15 minutes | Office | 2023 | 14 | 36 | $1,015 | $346.20 | 34.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 28 | 31 | $420.00 | $260.40 | 62.0% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 17 | 18 | $486.00 | $224.64 | 46.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 21 | 22 | $462.00 | $218.61 | 47.3% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 11 | 11 | $370.00 | $181.06 | 48.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 21 | 22 | $342.00 | $161.03 | 47.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 16 | 17 | $480.10 | $153.48 | 32.0% |
| 82044 | Urine microalbumin (protein) analysis | Office | 2023 | 20 | 20 | $220.00 | $116.76 | 53.1% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 12 | 12 | $204.00 | $56.50 | 27.7% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 18 | 18 | $295.00 | $53.36 | 18.1% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 79 | 453 | $33,975 | $16,929 | 49.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 103 | 103 | $22,784 | $13,049 | 57.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 92 | 194 | $19,206 | $10,470 | 54.5% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 44 | 197 | $12,805 | $8,091 | 63.2% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 78 | 78 | $9,360 | $6,284 | 67.1% |
| 97110 | Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | Office | 2022 | 33 | 198 | $8,712 | $3,673 | 42.2% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2022 | 52 | 119 | $7,140 | $3,581 | 50.2% |
| 97112 | Therapy procedure to re-educate brain-to-nerve-to-muscle function, each 15 minutes | Office | 2022 | 36 | 106 | $4,876 | $2,643 | 54.2% |
About Dr. Manuel Sanchez, M.D
Dr. Manuel Sanchez, M.D is a Adult Medicine healthcare provider based in Mcallen, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1669485504.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Manuel Sanchez, M.D has received a total of $65,933 in payments from pharmaceutical and medical device companies, with $1,586 received in 2024. These payments were reported across 282 transactions from 38 companies. The most common payment nature is "" ($58,205).
As a Medicare-enrolled provider, Sanchez has provided services to 7,454 Medicare beneficiaries, totaling 20,215 services with total Medicare billing of $402,794. Data is available for 4 years (2020–2023), covering 148 distinct procedure/service records.
Ad
Practice Information
- Specialty Adult Medicine
- Other Specialties Family Medicine
- Location Mcallen, TX
- Active Since 08/14/2006
- Last Updated 12/23/2015
- Taxonomy Code 207QA0505X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1669485504
Products in Payments
- M22 (Device) $595.03
- DAXXIFY (Drug) $560.53
- FARXIGA (Drug) $513.43
- Ozempic (Drug) $372.92
- Repatha (Biological) $368.00
- BOTOX (Biological) $281.95
- JARDIANCE (Drug) $231.39
- Prolia (Biological) $229.96
- EUCRISA (Drug) $228.03
- BEVESPI AEROSPHERE (Drug) $221.47
- XARELTO (Drug) $194.86
- Linzess (Drug) $165.36
- Victoza (Drug) $147.54
- LYRICA (Drug) $139.82
- TRULICITY (Drug) $128.17
- BREZTRI (Drug) $125.00
- BOTOX COSMETIC (Biological) $122.89
- INTERSTIM (Device) $118.48
- DALIRESP (Drug) $114.90
- RYBELSUS (Drug) $113.23
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.